kynurenine has been researched along with Cognitive Decline in 21 studies
Kynurenine: A metabolite of the essential amino acid tryptophan metabolized via the tryptophan-kynurenine pathway.
kynurenine : A ketone that is alanine in which one of the methyl hydrogens is substituted by a 2-aminobenzoyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Type I and II interferons (IFNs) stimulate the KYN/TRP pathway, producing elevated QA/kynurenic acid (KA), a potential neurotoxic imbalance that may contribute to SLE-mediated cognitive dysfunction." | 8.12 | Associations between circulating interferon and kynurenine/tryptophan pathway metabolites: support for a novel potential mechanism for cognitive dysfunction in SLE. ( Anderson, EW; Aranow, C; Arazi, A; Diamond, B; Furie, RA; Goodwin, S; Jin, Y; Mackay, M; Roeser, J; Shih, A; Volpe, B, 2022) |
| "Tryptophan and its catabolites (TRYCATs) have been suggested to link peripheral immune system activation and central neurotransmitter abnormalities with relevance to the etio-pathophysiology of schizophrenia (SZ) and major depressive disorder (MDD)." | 8.02 | Quinolinic acid is associated with cognitive deficits in schizophrenia but not major depressive disorder. ( Cathomas, F; Guetter, K; Kaiser, S; Klaus, F; Seifritz, E, 2021) |
| " In individuals with prediabetes, 3-hydroxykynurenine (OR per SD 0." | 8.02 | Associations between plasma kynurenines and cognitive function in individuals with normal glucose metabolism, prediabetes and type 2 diabetes: the Maastricht Study. ( Bakker, L; Dagnelie, PC; Eussen, SJPM; Köhler, S; Midttun, Ø; Ramakers, IHGB; Schram, MT; Stehouwer, CDA; Ueland, PM; van Boxtel, MPJ; van der Kallen, CJH; van Greevenbroek, MMJ; Verhey, FRJ; Wesselius, A, 2021) |
| "Several studies suggest a pathophysiologically relevant association between increased brain levels of the neuroinhibitory tryptophan metabolite kynurenic acid and cognitive dysfunctions in people with schizophrenia." | 7.88 | Maternal genotype determines kynurenic acid levels in the fetal brain: Implications for the pathophysiology of schizophrenia. ( Beggiato, S; Giorgini, F; Notarangelo, FM; Sathyasaikumar, KV; Schwarcz, R, 2018) |
| "Chronic low-grade inflammation is suggested to play a pathophysiological role in bipolar disorder (BD) and its related cognitive dysfunctions." | 5.72 | The Role of Kynurenines in Cognitive Dysfunction in Bipolar Disorder. ( Giltay, EJ; Hebbrecht, K; Morrens, M; Sabbe, B; van den Ameele, S; van Nuijs, ALN, 2022) |
| "In 58 cognitively normal, 396 mild cognitive impairment, and 112 AD participants from the Alzheimer's Disease Neuroimaging Initiative-1 (ADNI1) cohort, serum markers of 5-HT, tryptophan, and Kyn were measured and their relationships investigated with immunologic markers, affect and functional outcomes, CSF markers of beta-amyloid (Aβ) and tau, and regional gray matter." | 5.62 | Inflammation, negative affect, and amyloid burden in Alzheimer's disease: Insights from the kynurenine pathway. ( Allenspach, K; Collazo-Martinez, AD; Dantzer, R; Hoth, N; Klinedinst, B; Larsen, B; Le, S; Li, T; Mochel, JP; Pappas, C; Pollpeter, A; Wang, Q; Willette, AA; Willette, SA, 2021) |
| "Sepsis was induced by cecal ligation/perforation (CLP)." | 5.43 | Disrupted Tryptophan Metabolism Induced Cognitive Impairment in a Mouse Model of Sepsis-associated Encephalopathy. ( Gao, R; Kan, MQ; Wang, SG; Yang, RH; Zhang, SG, 2016) |
| " Type I and II interferons (IFNs) stimulate the KYN/TRP pathway, producing elevated QA/kynurenic acid (KA), a potential neurotoxic imbalance that may contribute to SLE-mediated cognitive dysfunction." | 4.12 | Associations between circulating interferon and kynurenine/tryptophan pathway metabolites: support for a novel potential mechanism for cognitive dysfunction in SLE. ( Anderson, EW; Aranow, C; Arazi, A; Diamond, B; Furie, RA; Goodwin, S; Jin, Y; Mackay, M; Roeser, J; Shih, A; Volpe, B, 2022) |
| "Tryptophan and its catabolites (TRYCATs) have been suggested to link peripheral immune system activation and central neurotransmitter abnormalities with relevance to the etio-pathophysiology of schizophrenia (SZ) and major depressive disorder (MDD)." | 4.02 | Quinolinic acid is associated with cognitive deficits in schizophrenia but not major depressive disorder. ( Cathomas, F; Guetter, K; Kaiser, S; Klaus, F; Seifritz, E, 2021) |
| " In individuals with prediabetes, 3-hydroxykynurenine (OR per SD 0." | 4.02 | Associations between plasma kynurenines and cognitive function in individuals with normal glucose metabolism, prediabetes and type 2 diabetes: the Maastricht Study. ( Bakker, L; Dagnelie, PC; Eussen, SJPM; Köhler, S; Midttun, Ø; Ramakers, IHGB; Schram, MT; Stehouwer, CDA; Ueland, PM; van Boxtel, MPJ; van der Kallen, CJH; van Greevenbroek, MMJ; Verhey, FRJ; Wesselius, A, 2021) |
| " Neuronal EAAT2 deletion leads to dysregulation of the kynurenine pathway, and astrocytic EAAT2 deficiency results in dysfunction of innate and adaptive immune pathways, which correlate with cognitive decline." | 3.91 | Divergent roles of astrocytic versus neuronal EAAT2 deficiency on cognition and overlap with aging and Alzheimer's molecular signatures. ( Gray, JD; Kazim, SF; Larson, CS; McEwen, BS; Pereira, AC; Ramakrishnan, A; Rosenberg, PA; Sharma, A; Shen, L, 2019) |
| "Several studies suggest a pathophysiologically relevant association between increased brain levels of the neuroinhibitory tryptophan metabolite kynurenic acid and cognitive dysfunctions in people with schizophrenia." | 3.88 | Maternal genotype determines kynurenic acid levels in the fetal brain: Implications for the pathophysiology of schizophrenia. ( Beggiato, S; Giorgini, F; Notarangelo, FM; Sathyasaikumar, KV; Schwarcz, R, 2018) |
| "Chronic low-grade inflammation is suggested to play a pathophysiological role in bipolar disorder (BD) and its related cognitive dysfunctions." | 1.72 | The Role of Kynurenines in Cognitive Dysfunction in Bipolar Disorder. ( Giltay, EJ; Hebbrecht, K; Morrens, M; Sabbe, B; van den Ameele, S; van Nuijs, ALN, 2022) |
| "Studies in Alzheimer's disease (AD) patients confirm KP dyshomeostasis in plasma and cerebrospinal fluid (CSF) which correlates with amyloid-β and tau pathology." | 1.72 | Systemic perturbations of the kynurenine pathway precede progression to dementia independently of amyloid-β. ( Bourgeat, P; Cespedes, M; Chatterjee, P; Doecke, JD; Fowler, CJ; Guillemin, GJ; Ittner, A; Jacobs, KR; Lim, CK; Lovejoy, DB; Martins, RN; Maruff, P; Masters, CL; Pertile, KK; Rainey-Smith, SR; Rembach, A; Rowe, CC; Rumble, RL; Trounson, B; Villemagne, VL, 2022) |
| "In 58 cognitively normal, 396 mild cognitive impairment, and 112 AD participants from the Alzheimer's Disease Neuroimaging Initiative-1 (ADNI1) cohort, serum markers of 5-HT, tryptophan, and Kyn were measured and their relationships investigated with immunologic markers, affect and functional outcomes, CSF markers of beta-amyloid (Aβ) and tau, and regional gray matter." | 1.62 | Inflammation, negative affect, and amyloid burden in Alzheimer's disease: Insights from the kynurenine pathway. ( Allenspach, K; Collazo-Martinez, AD; Dantzer, R; Hoth, N; Klinedinst, B; Larsen, B; Le, S; Li, T; Mochel, JP; Pappas, C; Pollpeter, A; Wang, Q; Willette, AA; Willette, SA, 2021) |
| "Cognitive dysfunction is a prominent feature of psychiatric disorders." | 1.56 | C-Reactive Protein as a Possible Predictor of Trail-Making Performance in Individuals with Psychiatric Disorders. ( Bengesser, SA; Birner, A; Dalkner, N; Falzberger, VS; Fellendorf, FT; Hamm, C; Lenger, M; Mangge, H; McIntyre, RS; Pilz, R; Platzer, M; Queissner, R; Reininghaus, B; Reininghaus, E; Rieger, A; Schwalsberger, K; Weiss, EM, 2020) |
| "Sepsis was induced by cecal ligation/perforation (CLP)." | 1.43 | Disrupted Tryptophan Metabolism Induced Cognitive Impairment in a Mouse Model of Sepsis-associated Encephalopathy. ( Gao, R; Kan, MQ; Wang, SG; Yang, RH; Zhang, SG, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (33.33) | 24.3611 |
| 2020's | 14 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Anderson, EW | 4 |
| Fishbein, J | 1 |
| Hong, J | 1 |
| Roeser, J | 4 |
| Furie, RA | 4 |
| Aranow, C | 4 |
| Volpe, BT | 1 |
| Diamond, B | 4 |
| Mackay, M | 4 |
| Hebbrecht, K | 1 |
| Morrens, M | 1 |
| Giltay, EJ | 1 |
| van Nuijs, ALN | 1 |
| Sabbe, B | 1 |
| van den Ameele, S | 1 |
| Samant, NP | 1 |
| Gupta, GL | 1 |
| Cespedes, M | 1 |
| Jacobs, KR | 1 |
| Maruff, P | 1 |
| Rembach, A | 1 |
| Fowler, CJ | 1 |
| Trounson, B | 1 |
| Pertile, KK | 1 |
| Rumble, RL | 1 |
| Rainey-Smith, SR | 1 |
| Rowe, CC | 1 |
| Villemagne, VL | 1 |
| Bourgeat, P | 1 |
| Lim, CK | 1 |
| Chatterjee, P | 1 |
| Martins, RN | 1 |
| Ittner, A | 1 |
| Masters, CL | 1 |
| Doecke, JD | 1 |
| Guillemin, GJ | 2 |
| Lovejoy, DB | 1 |
| Jin, Y | 3 |
| Shih, A | 3 |
| Arazi, A | 3 |
| Goodwin, S | 3 |
| Volpe, B | 3 |
| Javani, G | 1 |
| Babri, S | 1 |
| Farajdokht, F | 1 |
| Ghaffari-Nasab, A | 1 |
| Mohaddes, G | 1 |
| Cysique, LA | 1 |
| Jakabek, D | 1 |
| Bracken, SG | 1 |
| Allen-Davidian, Y | 1 |
| Heng, B | 1 |
| Chow, S | 1 |
| Dehhaghi, M | 1 |
| Staats Pires, A | 1 |
| Darley, DR | 1 |
| Byrne, A | 1 |
| Phetsouphanh, C | 1 |
| Kelleher, A | 1 |
| Dore, GJ | 1 |
| Matthews, GV | 1 |
| Brew, BJ | 1 |
| Sharma, A | 1 |
| Kazim, SF | 1 |
| Larson, CS | 1 |
| Ramakrishnan, A | 1 |
| Gray, JD | 1 |
| McEwen, BS | 1 |
| Rosenberg, PA | 1 |
| Shen, L | 1 |
| Pereira, AC | 1 |
| Imbeault, S | 1 |
| Goiny, M | 1 |
| Liu, X | 1 |
| Erhardt, S | 1 |
| Ramirez Ortega, D | 1 |
| Ovalle Rodríguez, P | 1 |
| Pineda, B | 1 |
| González Esquivel, DF | 1 |
| Ramos Chávez, LA | 1 |
| Vázquez Cervantes, GI | 1 |
| Roldán Roldán, G | 1 |
| Pérez de la Cruz, G | 1 |
| Díaz Ruiz, A | 1 |
| Méndez Armenta, M | 1 |
| Marcial Quino, J | 1 |
| Gómez Manzo, S | 1 |
| Ríos, C | 1 |
| Pérez de la Cruz, V | 1 |
| Karpińska, G | 1 |
| Dobrowolski, JC | 1 |
| Yinda, CK | 1 |
| Rector, A | 1 |
| Zeller, M | 1 |
| Conceição-Neto, N | 1 |
| Heylen, E | 1 |
| Maes, P | 1 |
| Ghogomu, SM | 1 |
| Van Ranst, M | 1 |
| Matthijnssens, J | 1 |
| Arthanari, SK | 1 |
| Vanitha, J | 1 |
| Ganesh, M | 1 |
| Venkateshwaran, K | 1 |
| de Lama Caro-Patón, G | 1 |
| García-Salido, A | 1 |
| Iglesias-Bouzas, MI | 1 |
| Guillén, M | 1 |
| Cañedo-Villaroya, E | 1 |
| Martínez-Romera, I | 1 |
| Serrano-González, A | 1 |
| Casado-Flores, J | 1 |
| Gale, P | 2 |
| Chen, X | 2 |
| Li, H | 1 |
| Lucero-Prisno, DE | 1 |
| Abdullah, AS | 1 |
| Huang, J | 1 |
| Laurence, C | 1 |
| Liang, X | 1 |
| Ma, Z | 1 |
| Mao, Z | 1 |
| Ren, R | 1 |
| Wu, S | 1 |
| Wang, N | 1 |
| Wang, P | 2 |
| Wang, T | 1 |
| Yan, H | 1 |
| Zou, Y | 1 |
| Olsen, KM | 1 |
| Gabler, NK | 1 |
| Rademacher, CJ | 1 |
| Schwartz, KJ | 1 |
| Schweer, WP | 1 |
| Gourley, GG | 1 |
| Patience, JF | 1 |
| Rauch, JC | 1 |
| Stokes, RS | 1 |
| Shike, DW | 1 |
| Luebbe, KM | 1 |
| Stalker, LA | 1 |
| Klopfenstein, TJ | 1 |
| Funston, RN | 1 |
| Unger, PA | 1 |
| Lighaam, LC | 1 |
| Vermeulen, E | 1 |
| Kruithof, S | 1 |
| Makuch, M | 1 |
| Culver, EL | 1 |
| van Bruggen, R | 1 |
| Remmerswaal, EBM | 1 |
| Ten Berge, IJM | 1 |
| Emmens, RW | 1 |
| Niessen, HWM | 1 |
| Barnes, E | 1 |
| Wolbink, GJ | 1 |
| van Ham, SM | 1 |
| Rispens, T | 1 |
| Liang, JX | 1 |
| Lin, J | 1 |
| Liu, J | 1 |
| Wang, X | 1 |
| Zhang, T | 1 |
| Li, J | 1 |
| Wu, Y | 2 |
| Venier, M | 1 |
| Salamova, A | 1 |
| Gonçales, VR | 1 |
| Lian, J | 1 |
| Gautam, S | 1 |
| Tilley, RD | 1 |
| Gooding, JJ | 1 |
| Kandel, YR | 1 |
| Bradley, CA | 1 |
| Chilvers, MI | 1 |
| Mathew, FM | 1 |
| Tenuta, AU | 1 |
| Smith, DL | 1 |
| Wise, KA | 1 |
| Mueller, DS | 1 |
| Lu, N | 1 |
| Lu, M | 1 |
| Liu, P | 1 |
| Xu, H | 1 |
| Qiu, X | 1 |
| Hu, S | 1 |
| Bai, S | 1 |
| Wu, J | 1 |
| Xue, S | 1 |
| Dai, X | 1 |
| Dharmage, SC | 1 |
| Abramson, MJ | 1 |
| Erbas, B | 1 |
| Bennett, CM | 1 |
| Svanes, C | 1 |
| Hui, J | 1 |
| Axelrad, C | 1 |
| Lowe, AJ | 1 |
| Lodge, CJ | 1 |
| Hoshi, M | 1 |
| Osawa, Y | 1 |
| Nakamoto, K | 1 |
| Morita, N | 1 |
| Yamamoto, Y | 1 |
| Ando, T | 1 |
| Tashita, C | 1 |
| Nabeshima, T | 1 |
| Saito, K | 1 |
| Gianesello, L | 1 |
| Del Prete, D | 1 |
| Ceol, M | 1 |
| Priante, G | 1 |
| Calò, LA | 1 |
| Anglani, F | 1 |
| Vekaria, HJ | 1 |
| Hubbard, WB | 1 |
| Scholpa, NE | 1 |
| Spry, ML | 1 |
| Gooch, JL | 1 |
| Prince, SJ | 1 |
| Schnellmann, RG | 1 |
| Sullivan, PG | 1 |
| Zhang, Q | 1 |
| Hu, R | 1 |
| Gu, Z | 1 |
| Zhang, M | 1 |
| Zhang, Z | 1 |
| Peng, Y | 1 |
| Feng, L | 1 |
| Li, X | 3 |
| Zhao, C | 1 |
| Sarfaraz, K | 1 |
| Gao, L | 1 |
| Wang, H | 1 |
| Wan, C | 1 |
| Leng, J | 1 |
| Yang, P | 1 |
| Gao, X | 1 |
| Gao, J | 1 |
| Emam, HE | 1 |
| Saad, NM | 1 |
| Abdallah, AEM | 1 |
| Ahmed, HB | 1 |
| Palombo, M | 1 |
| Ianus, A | 1 |
| Guerreri, M | 1 |
| Nunes, D | 1 |
| Alexander, DC | 1 |
| Shemesh, N | 1 |
| Zhang, H | 1 |
| Xiong, Q | 1 |
| Liu, YS | 1 |
| Hu, LX | 1 |
| Shi, ZQ | 1 |
| Ying, GG | 1 |
| Chen, R | 1 |
| Hong, X | 1 |
| Yan, S | 1 |
| Zha, J | 1 |
| Gu, H | 1 |
| Zhong, Q | 1 |
| Zeng, Y | 1 |
| Zhang, S | 1 |
| Bu, Y | 1 |
| Farghali, M | 1 |
| Mayumi, M | 1 |
| Syo, K | 1 |
| Satoshi, A | 1 |
| Seiichi, Y | 1 |
| Takashima, S | 1 |
| Ono, H | 1 |
| Ap, Y | 1 |
| Yamashiro, T | 1 |
| Ahmed, MM | 1 |
| Kotb, S | 1 |
| Iwasaki, M | 1 |
| Ihara, I | 1 |
| Umetsu, K | 1 |
| Hu, B | 1 |
| Wang, Y | 2 |
| Quan, J | 1 |
| Huang, K | 1 |
| Gu, X | 1 |
| Zhu, J | 1 |
| Yan, Y | 1 |
| Wu, P | 1 |
| Yang, L | 1 |
| Zhao, J | 1 |
| Koók, L | 1 |
| Nemestóthy, N | 1 |
| Bélafi-Bakó, K | 1 |
| Bakonyi, P | 1 |
| Luo, X | 1 |
| Zhang, F | 1 |
| Li, Q | 1 |
| Xia, Q | 1 |
| Li, Z | 1 |
| Ye, W | 1 |
| Li, S | 1 |
| Ge, C | 1 |
| Zakkula, A | 1 |
| Pulipati, S | 1 |
| Dittakavi, S | 1 |
| Bestha, RM | 1 |
| Zainuddin, M | 1 |
| Trivedi, RK | 1 |
| Mullangi, R | 1 |
| Lo, GH | 1 |
| Lin, CW | 1 |
| Tai, CM | 1 |
| Perng, DS | 1 |
| Chen, IL | 1 |
| Yeh, JH | 1 |
| Lin, HC | 1 |
| Rocha, GS | 1 |
| Silva, MKL | 1 |
| Cesarino, I | 1 |
| Hazzaa, SM | 1 |
| Abdelaziz, SAM | 1 |
| Abd Eldaim, MA | 1 |
| Abdel-Daim, MM | 1 |
| Elgarawany, GE | 1 |
| Larsson, P | 1 |
| Ljuslinder, I | 1 |
| Öhlund, D | 1 |
| Myte, R | 1 |
| Löfgren-Burström, A | 1 |
| Zingmark, C | 1 |
| Ling, A | 1 |
| Edin, S | 1 |
| Palmqvist, R | 1 |
| Murthi, P | 1 |
| Rajaraman, G | 1 |
| Erwich, JJHM | 1 |
| Dimitriadis, E | 1 |
| Yoon, HG | 1 |
| Oh, D | 1 |
| Ahn, YC | 1 |
| Noh, JM | 1 |
| Pyo, H | 1 |
| Cho, WK | 1 |
| Song, YM | 1 |
| Park, M | 1 |
| Hwang, NY | 1 |
| Sun, JM | 1 |
| Kim, HK | 1 |
| Zo, JI | 1 |
| Shim, YM | 1 |
| Persano, A | 1 |
| Quaranta, F | 1 |
| Taurino, A | 1 |
| Siciliano, PA | 1 |
| Iannacci, J | 1 |
| Malekbala, MR | 1 |
| Soltani, S | 1 |
| Abdul Rashid, S | 1 |
| Abdullah, LC | 1 |
| Rashid, U | 1 |
| Nehdi, IA | 1 |
| Choong, TSY | 1 |
| Teo, SH | 1 |
| Xu, P | 1 |
| Yan, F | 1 |
| Zhao, Y | 1 |
| Sun, S | 1 |
| Ying, L | 1 |
| Quinzi, V | 1 |
| Caruso, S | 1 |
| Mummolo, S | 1 |
| Nota, A | 1 |
| Angelone, AM | 1 |
| Mattei, A | 1 |
| Gatto, R | 1 |
| Marzo, G | 1 |
| Xin, W | 1 |
| Severino, J | 1 |
| Venkert, A | 1 |
| Yu, H | 1 |
| Knorr, D | 1 |
| Yang, JM | 1 |
| Carlson, L | 1 |
| Hicks, R | 1 |
| De Rosa, I | 1 |
| Beckmann, NA | 1 |
| Bitsch, RG | 1 |
| Schonhoff, M | 1 |
| Siebenrock, KA | 1 |
| Schwarze, M | 1 |
| Jaeger, S | 1 |
| Bai, JH | 1 |
| Zheng, YL | 1 |
| Yu, YP | 1 |
| Dalkner, N | 1 |
| Reininghaus, E | 1 |
| Schwalsberger, K | 1 |
| Rieger, A | 1 |
| Hamm, C | 1 |
| Pilz, R | 1 |
| Lenger, M | 1 |
| Queissner, R | 1 |
| Falzberger, VS | 1 |
| Platzer, M | 1 |
| Fellendorf, FT | 1 |
| Birner, A | 1 |
| Bengesser, SA | 1 |
| Weiss, EM | 1 |
| McIntyre, RS | 1 |
| Mangge, H | 1 |
| Reininghaus, B | 1 |
| Willette, AA | 1 |
| Pappas, C | 1 |
| Hoth, N | 1 |
| Wang, Q | 1 |
| Klinedinst, B | 1 |
| Willette, SA | 1 |
| Larsen, B | 1 |
| Pollpeter, A | 1 |
| Li, T | 1 |
| Le, S | 1 |
| Collazo-Martinez, AD | 1 |
| Mochel, JP | 1 |
| Allenspach, K | 1 |
| Dantzer, R | 1 |
| Cathomas, F | 1 |
| Guetter, K | 1 |
| Seifritz, E | 1 |
| Klaus, F | 1 |
| Kaiser, S | 1 |
| Bakker, L | 1 |
| Ramakers, IHGB | 1 |
| van Boxtel, MPJ | 1 |
| Schram, MT | 1 |
| Stehouwer, CDA | 1 |
| van der Kallen, CJH | 1 |
| Dagnelie, PC | 1 |
| van Greevenbroek, MMJ | 1 |
| Wesselius, A | 1 |
| Midttun, Ø | 1 |
| Ueland, PM | 1 |
| Verhey, FRJ | 1 |
| Eussen, SJPM | 1 |
| Köhler, S | 1 |
| Koola, MM | 1 |
| Sklar, J | 1 |
| Davis, W | 1 |
| Nikiforuk, A | 1 |
| Meissen, JK | 1 |
| Sawant-Basak, A | 1 |
| Aaronson, ST | 1 |
| Kozak, R | 1 |
| Sharma, R | 1 |
| Razdan, K | 1 |
| Bansal, Y | 1 |
| Kuhad, A | 1 |
| Beggiato, S | 1 |
| Notarangelo, FM | 1 |
| Sathyasaikumar, KV | 1 |
| Giorgini, F | 1 |
| Schwarcz, R | 1 |
| Gao, R | 1 |
| Kan, MQ | 1 |
| Wang, SG | 1 |
| Yang, RH | 1 |
| Zhang, SG | 1 |
| Rommer, PS | 1 |
| Fuchs, D | 1 |
| Leblhuber, F | 1 |
| Schroth, R | 1 |
| Greilberger, M | 1 |
| Tafeit, E | 1 |
| Greilberger, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Proof-of Concept Trial of Galantamine and Memantine for Cognitive Impairments in Schizophrenia: Is the Combination Effective?[NCT02234752] | Phase 2 | 3 participants (Actual) | Interventional | 2014-09-30 | Terminated (stopped due to Funding no longer available and PI no longer working at the institution) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The primary outcome measure will be the change in level of cognition as measured by the MATRICS Consensus Cognitive Battery (MCCB). In schizophrenia, usual composite scores are 20-39. In healthy controls, usual composite scores are normalized to 40-60. Higher values of composite scores mean better cognition. Test scores are normalized to healthy controls, therefore no min-max range is available. Final scores calculated by MATRICS Consensus Cognitive Battery software. Exact minimum/maximum are not known to provider. Overall composite scores are reported. (NCT02234752)
Timeframe: Baseline and 6-Weeks
| Intervention | units on a scale (Number) | ||||
|---|---|---|---|---|---|
| Baseline Participant 1 | Week 6 Participant 1 | Baseline Participant 2 | Week 6 Participant 2 | Baseline Participant 3 | |
| Galantamine ER, Memantine XR | 48 | 48 | 32 | 25 | 9 |
The secondary outcome measure will be change in metabolite values. Values were collected in triplicate. (NCT02234752)
Timeframe: Baseline and 6-Weeks
| Intervention | µM (Mean) | ||||
|---|---|---|---|---|---|
| Baseline tryptophan Participant 1 | Week-6 tryptophan Participant 1 | Baseline tryptophan Participant 2 | Week-6 tryptophan Participant 2 | Baseline tryptophan Participant 3 | |
| KP Metabolites Values | 51.94 | 55.72 | 32.17 | 24.96 | 35.07 |
The secondary outcome measure will be change in metabolite values. Values were collected in triplicate. AUC ratio reported. (NCT02234752)
Timeframe: Baseline and 6-Weeks
| Intervention | AUC Ratio (Number) | ||||
|---|---|---|---|---|---|
| Baseline KYN/TRP Participant 1 | Week-6 KYN/TRP Participant 1 | Baseline KYN/TRP Participant 2 | Week-6 KYN/TRP Participant 2 | Baseline KYN/TRP Participant 3 | |
| KP Metabolites Values | 1.21 | 1.31 | 1.06 | 0.8 | 0.79 |
The secondary outcome measure will be change in metabolite values. Values were collected in triplicate. AUC ratio reported. (NCT02234752)
Timeframe: Baseline and 6-Weeks
| Intervention | AUC Ratio (Number) | ||||
|---|---|---|---|---|---|
| Baseline KYNA/KYN Participant 1 | Week-6 KYNA/KYN Participant 1 | Baseline KYNA/KYN Participant 2 | Week-6 KYNA/KYN Participant 2 | Baseline KYNA/KYN Participant 3 | |
| KP Metabolites Values | 0.075 | 0.050 | 0.121 | 0.114 | 0.152 |
The secondary outcome measure will be change in metabolite values. Values were collected in triplicate. MS* AUC is mass spectrometry times area under the curve. (NCT02234752)
Timeframe: Baseline and 6-Weeks
| Intervention | MS* AUC (Mean) | ||||
|---|---|---|---|---|---|
| Baseline KYNA Participant 1 | Week-6 KYNA Participant 1 | Baseline KYNA Participant 2 | Week-6 KYNA Participant 2 | Baseline KYNA Participant 3 | |
| KP Metabolites Values | 103911 | 83737 | 95139 | 73280 | 93163 |
The secondary outcome measure will be change in metabolite values. Values were collected in triplicate. (NCT02234752)
Timeframe: Baseline and 6-Weeks
| Intervention | µM (Mean) | ||||
|---|---|---|---|---|---|
| Baseline KYN Participant 1 | Week-6 KYN Participant 1 | Baseline KYN Participant 2 | Week-6 KYN Participant 2 | Baseline KYN Participant 3 | |
| KP Metabolites Values | 1.62 | 1.85 | 0.86 | 0.71 | 0.76 |
The secondary outcome measure will be change in metabolite values. Values were collected in triplicate. AUC ratio reported. (NCT02234752)
Timeframe: Baseline and 6-Weeks
| Intervention | AUC Ratio (Number) | ||||
|---|---|---|---|---|---|
| Baseline PIC/KYN Participant 1 | Week-6 PIC/KYN Participant 1 | Baseline PIC/KYN Participant 2 | Week-6 PIC/KYN Participant 2 | Baseline PIC/KYN Participant 3 | |
| KP Metabolites Values | 0.0317 | 0.0175 | 0.1039 | 0.0989 | 0.0655 |
The secondary outcome measure will be change in metabolite values. Values were collected in triplicate. MS* AUC is mass spectrometry times area under the curve. (NCT02234752)
Timeframe: Baseline and 6-Weeks
| Intervention | MS* AUC (Mean) | ||||
|---|---|---|---|---|---|
| Baseline PIC Participant 1 | Week-6 PIC Participant 1 | Baseline PIC Participant 2 | Week-6 PIC Participant 2 | Baseline PIC Participant 3 | |
| KP Metabolites Values | 44021 | 29542 | 81883 | 63745 | 40189 |
2 reviews available for kynurenine and Cognitive Decline
| Article | Year |
|---|---|
Topics: Acetaminophen; Administration, Oral; Adolescent; Adsorption; Adult; Allyl Compounds; Amylopectin; Am | 2013 |
Rollercoaster ride of kynurenines: steering the wheel towards neuroprotection in Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Cognitive Dysfunction; Drug Development; Humans; Kynurenic Acid; Kynuren | 2018 |
3 trials available for kynurenine and Cognitive Decline
| Article | Year |
|---|---|
Topics: Acetaminophen; Administration, Oral; Adolescent; Adsorption; Adult; Allyl Compounds; Amylopectin; Am | 2013 |
Kynurenine pathway in schizophrenia: Galantamine-memantine combination for cognitive impairments.
Topics: Adolescent; Adult; Cognitive Dysfunction; Drug Therapy, Combination; Female; Galantamine; Humans; Ky | 2018 |
Lowered Levels of Carbonyl Proteins after Vitamin B Supplementation in Patients with Mild Cognitive Impairment and Alzheimer's Disease.
Topics: Age Factors; Aged; Alzheimer Disease; Biomarkers; Cognitive Dysfunction; Dietary Supplements; Discri | 2016 |
17 other studies available for kynurenine and Cognitive Decline
| Article | Year |
|---|---|
Quinolinic acid, a kynurenine/tryptophan pathway metabolite, associates with impaired cognitive test performance in systemic lupus erythematosus.
Topics: Cognitive Dysfunction; Cross-Sectional Studies; Humans; Kynurenine; Lupus Erythematosus, Systemic; N | 2021 |
The Role of Kynurenines in Cognitive Dysfunction in Bipolar Disorder.
Topics: Bipolar Disorder; Cognitive Dysfunction; Humans; Inflammation; Kynurenic Acid; Kynurenine; Tryptopha | 2022 |
Gossypetin- based therapeutics for cognitive dysfunction in chronic unpredictable stress- exposed mice.
Topics: Animals; Brain-Derived Neurotrophic Factor; Cognitive Dysfunction; Corticosterone; Disease Models, A | 2022 |
Systemic perturbations of the kynurenine pathway precede progression to dementia independently of amyloid-β.
Topics: 3-Hydroxyanthranilic Acid; Alzheimer Disease; Amyloid beta-Peptides; Australia; Biomarkers; Cognitiv | 2022 |
Associations between circulating interferon and kynurenine/tryptophan pathway metabolites: support for a novel potential mechanism for cognitive dysfunction in SLE.
Topics: Cognitive Dysfunction; Humans; Interferons; Kynurenic Acid; Kynurenine; Lupus Erythematosus, Systemi | 2022 |
Associations between circulating interferon and kynurenine/tryptophan pathway metabolites: support for a novel potential mechanism for cognitive dysfunction in SLE.
Topics: Cognitive Dysfunction; Humans; Interferons; Kynurenic Acid; Kynurenine; Lupus Erythematosus, Systemi | 2022 |
Associations between circulating interferon and kynurenine/tryptophan pathway metabolites: support for a novel potential mechanism for cognitive dysfunction in SLE.
Topics: Cognitive Dysfunction; Humans; Interferons; Kynurenic Acid; Kynurenine; Lupus Erythematosus, Systemi | 2022 |
Associations between circulating interferon and kynurenine/tryptophan pathway metabolites: support for a novel potential mechanism for cognitive dysfunction in SLE.
Topics: Cognitive Dysfunction; Humans; Interferons; Kynurenic Acid; Kynurenine; Lupus Erythematosus, Systemi | 2022 |
Associations between circulating interferon and kynurenine/tryptophan pathway metabolites: support for a novel potential mechanism for cognitive dysfunction in SLE.
Topics: Cognitive Dysfunction; Humans; Interferons; Kynurenic Acid; Kynurenine; Lupus Erythematosus, Systemi | 2022 |
Associations between circulating interferon and kynurenine/tryptophan pathway metabolites: support for a novel potential mechanism for cognitive dysfunction in SLE.
Topics: Cognitive Dysfunction; Humans; Interferons; Kynurenic Acid; Kynurenine; Lupus Erythematosus, Systemi | 2022 |
Associations between circulating interferon and kynurenine/tryptophan pathway metabolites: support for a novel potential mechanism for cognitive dysfunction in SLE.
Topics: Cognitive Dysfunction; Humans; Interferons; Kynurenic Acid; Kynurenine; Lupus Erythematosus, Systemi | 2022 |
Associations between circulating interferon and kynurenine/tryptophan pathway metabolites: support for a novel potential mechanism for cognitive dysfunction in SLE.
Topics: Cognitive Dysfunction; Humans; Interferons; Kynurenic Acid; Kynurenine; Lupus Erythematosus, Systemi | 2022 |
Associations between circulating interferon and kynurenine/tryptophan pathway metabolites: support for a novel potential mechanism for cognitive dysfunction in SLE.
Topics: Cognitive Dysfunction; Humans; Interferons; Kynurenic Acid; Kynurenine; Lupus Erythematosus, Systemi | 2022 |
Mitotherapy restores hippocampal mitochondrial function and cognitive impairment in aged male rats subjected to chronic mild stress.
Topics: Adenosine Triphosphate; Animals; Cognitive Dysfunction; Hippocampus; Kynurenine; Male; Rats; Rats, W | 2023 |
The kynurenine pathway relates to post-acute COVID-19 objective cognitive impairment and PASC.
Topics: Adult; Biomarkers; Cognitive Dysfunction; COVID-19; Female; Humans; Kynurenine; Male; Middle Aged; P | 2023 |
Divergent roles of astrocytic versus neuronal EAAT2 deficiency on cognition and overlap with aging and Alzheimer's molecular signatures.
Topics: Adult; Aged, 80 and over; Aging; Alzheimer Disease; Animals; Astrocytes; Cognition; Cognitive Dysfun | 2019 |
Effects of IDO1 and TDO2 inhibition on cognitive deficits and anxiety following LPS-induced neuroinflammation.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Behavior, Animal; Brain; Cognitive Dysfunction; Enzyme Inhibi | 2020 |
Kynurenine Pathway as a New Target of Cognitive Impairment Induced by Lead Toxicity During the Lactation.
Topics: Animals; Brain; Cognitive Dysfunction; Environmental Exposure; Female; Kynurenine; Lactation; Lead; | 2020 |
Urinary kynurenine as a biomarker for Parkinson's disease.
Topics: Biomarkers; Cognitive Dysfunction; Humans; Kynurenine; Parkinson Disease; Triglycerides | 2021 |
C-Reactive Protein as a Possible Predictor of Trail-Making Performance in Individuals with Psychiatric Disorders.
Topics: Adult; Aged; Biomarkers; C-Reactive Protein; Cognitive Dysfunction; Female; Humans; Inflammation; In | 2020 |
Inflammation, negative affect, and amyloid burden in Alzheimer's disease: Insights from the kynurenine pathway.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Cognitive Dysfunction; Humans; Inflammation; Kynurenine | 2021 |
Quinolinic acid is associated with cognitive deficits in schizophrenia but not major depressive disorder.
Topics: Adult; Case-Control Studies; Cognition; Cognitive Dysfunction; Depressive Disorder, Major; Female; H | 2021 |
Associations between plasma kynurenines and cognitive function in individuals with normal glucose metabolism, prediabetes and type 2 diabetes: the Maastricht Study.
Topics: 3-Hydroxyanthranilic Acid; Aged; Biomarkers; Blood Glucose; Cognition; Cognitive Dysfunction; Cross- | 2021 |
Maternal genotype determines kynurenic acid levels in the fetal brain: Implications for the pathophysiology of schizophrenia.
Topics: Animals; Brain; Cognitive Dysfunction; Female; Genotype; Kynurenic Acid; Kynurenine; Kynurenine 3-Mo | 2018 |
Disrupted Tryptophan Metabolism Induced Cognitive Impairment in a Mouse Model of Sepsis-associated Encephalopathy.
Topics: Animals; Cecum; Cognitive Dysfunction; Disease Models, Animal; Enzyme Activation; Indoleamine-Pyrrol | 2016 |